Phase III
The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
In a Phase III study, Eli Lilly’s Verzenio combined with standard adjuvant endocrine therapy met its primary endpoint of invasive disease-free survival in high-risk breast cancer and significantly reduced the risk of a recurrence of the disease.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
Eli Lilly will assess its JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Although clinical trials are often performed throughout different parts of the world, often their demographic makeup—the gender, age and race of participants—has a certain kind of uniformity.
Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.
Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020, speaking Thursday in a virtual session.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
PRESS RELEASES